Resveratrol suppresses the myofibroblastic phenotype and fibrosis formation in kidneys via proliferation‐related signalling pathways. (28th November 2019)

• Record Type: Journal Article
• Authors: Zhang, Xing; Lu, Hong; Xie, Shuangshuang; Wu, Cunzao; Guo, Yangyang; Xiao, Yanyi; Zheng, Shizhang; Zhu, Hengyue; Zhang, Yan; Bai, Yongheng
• Is Part Of: British journal of pharmacology. Volume 176:Number 24(2019)
• Page Start: 4745
• Page End: 4759
• Publication Date: 2019-11-28
• Subjects: Pharmacology -- Periodicals; Chemotherapy -- Periodicals; Drug Therapy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1111/bph.14842
• Languages: English
• ISSNs: 0007-1188

Abstract

Abstract : Background and Purpose: Renal fibrosis acts as the common pathway leading to the development of end‐stage renal disease. Previous studies have shown that resveratrol has anti‐fibrotic activity, but its potential molecular mechanisms of action are not well understood. Experimental Approach: The anti‐fibrotic effects of resveratrol were assayed in a rat model of unilateral ureteral obstruction (UUO) in vivo and in fibroblasts and tubular epithelial cells (TECs) stimulated by TGF‐β1 in vitro. Gene and protein expression levels were analysed by PCR, Western blotting, and immunohistochemical staining. Key Results: Resveratrol inhibits the myofibroblastic phenotype and fibrosis formation in UUO kidneys by targeting fibroblast–myofibroblast differentiation (FMD) and epithelial–mesenchymal transition (EMT). The anti‐fibrotic effects of resveratrol correlated with decreased proliferation of TECs in the interstitium and tubules, resulting in suppressed activity of the proliferation‐related signalling pathways, including that of the MAPK, PI3K/Akt, Wnt/β‐catenin, and JAK2/STAT3 pathways. Resveratrol treatment suppressed TGF‐β1‐induced FMD and the expression of the myofibroblastic phenotype in fibroblasts in vitro by antagonizing the activation of proliferation‐related signalling. Similarly, TGF‐β1‐mediated overactivation of the proliferation‐related signalling in TECs induced EMT, and the myofibroblastic phenotype was suppressed by resveratrol. The anti‐fibrotic and anti‐proliferative effects of resveratrol were associated with the inactivation of Smad2/3 signalling and resulted in a partial reversal of FMD and EMT and the inhibition of the myofibroblastic phenotype. Conclusions and Implications: Resveratrol suppresses the myofibroblastic phenotype and fibrosis formation in vivo and in vitro via proliferation‐related pathways, making it a potential therapeutic agent for preventing renal fibrosis.